Table 1 summarizes the main TCEs currently in clinical development targeting PSMA, STEAP1, or DLL3 in advanced PCa. Early trials demonstrated that TCEs can induce prostate-specific antigen (PSA) decline and objective response rate (ORR) in patients with mCRPC who have exhausted conventional therapies, albeit with some challenges in tolerability and durability [12,26,27]. This evidence concerns the gene KLK3 and posterior cortical atrophy.